The weight-loss effectiveness of Arena Pharmaceuticals Inc.’s lorcaserin in some patients during Phase III trials reassured some members of the Endocrinologic and Metabolic Drugs Advisory Committee May 10 about the drug’s efficacy, even though it met only one of two weight-loss criteria set by FDA.
Despite what many members considered limited efficacy, the panel found 18-4, with one abstention, that the benefit is sufficient to offset the risk presented by signals of valvular heart disease, which they said could be assessed post-marketing Also see "
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?